150
Participants
Start Date
February 28, 2005
Primary Completion Date
August 31, 2006
Study Completion Date
March 31, 2008
Dasatinib
Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
Imatinib
Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
Local Institution, Birmingham
Local Institution, Anaheim
Local Institution, Bakersfield
Local Institution, Fullerton
Local Institution, Loma Linda
Local Institution, Los Angeles
Local Institution, Monterey Park
Local Institution, San Diego
Local Institution, Santa Barbara
Local Institution, Santa Maria
Local Institution, Stanford
Local Institution, Vallejo
Local Institution, Aurora
Local Institution, Hartford
Local Institution, Washington D.C.
Local Institution, Jacksonville
Local Institution, Tampa
Local Institution, Athens
Local Institution, Atlanta
Local Institution, Lawrenceville
Local Institution, Tucker
Local Institution, Chicago
Local Institution, Peoria
Local Institution, Indianapolis
Local Institution, Kansas City
Local Institution, Lexington
Local Institution, Boston
Local Institution, Minneapolis
Local Institution, Rochester
Local Institution, Columbia
Local Institution, Kansas City
Local Institution, St Louis
Local Institution, Omaha
Local Institution, Hackensack
Local Institution, Morristown
Local Institution, New Brunswick
Local Institution, Cary
Local Institution, Chapel Hill
Local Institution, Oklahoma City
Local Institution, Tulsa
Local Institution, Portland
Local Institution, Pittsburgh
Local Institution, Greenville
Local Institution, Nashville
Local Institution, Dallas
Local Institution, Fort Worth
Local Institution, Houston
Local Institution, San Antonio
Local Institution, Tyler
Local Institution, Norfolk
Local Institution, Seattle
Local Institution, Spokane
Local Institution, Vancouver
Local Institution, Buenos Aires
Local Institution, Córdoba
Local Institution, Camperdown
Local Institution, St Leonards
Local Institution, South Brisbane
Local Institution, Adelaide
Local Institution, Perth
Local Institution, Wein
Local Institution, B-Leuven
Local Institution, Bruges
Local Institution, Brussels
Local Institution, Charleroi
Local Institution, Edegem
Local Institution, Yvoir
Local Institution, Curitiba
Local Institution, Rio de Janeiro
Local Institution, São Paulo
Local Institution, Edmonton
Local Institution, Vancouver
Local Institution, Toronto
Local Institution, Montreal
Local Institution, Beijing
Local Institution, Shanghai
Local Institution, Aarhus
Local Institution, Tallinn
Local Institution, Helsinki
Local Institution, Lille
Local Institution, Lyon
Local Institution, Nantes
Local Institution, Paris
Local Institution, Pessac
Local Institution, Poitiers
Local Institution, Strasbourg
Local Institution, Dresden
Local Institution, Groenkloof
Local Institution, Hamburg
Local Institution, Leipzig
Local Institution, Mainz
Local Institution, Mannheim
Local Institution, Budapest
Local Institution, Dublin
Local Institution, Ramat Gan
Local Institution, Bari
Local Institution, Bologna
Local Institution, Milan
Local Institution, Napoli
Local Institution, Orbassano
Local Institution, Roma
Local Institution, Trondheim
Local Institution, Lima
Local Institution, Quezon City
Local Institution, Katowice
Local Institution, Krakow
Local Institution, Lublin
Local Institution, Warsaw
Local Institution, San Juan
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Singapore
Local Institution, Bloemfontein
Local Institution, Parktown
Local Institution, Soweto
Local Institution, Kyunggi-Do
Local Institution, Barcelona
Local Institution, Madrid
Local Institution, Gothenburg
Local Institution, Lund
Local Institution, Stockholm
Local Institution, Umeå
Local Institution, Uppsala
Local Institution, Basel
Local Institution, Bellinzona
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution, Bangkok
Local Institution, Glasglow
Local Institution, London
Local Institution, Newcastle
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY